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Abstract 
 
The control of placental hormone biosynthesis 
is critical during gestation, since their coordinated 
action is essential for the normal progress of pregnancy. 
Hormonal synthesis regulation in placenta is still not 
elucidated and differs from that observed in other 
steroidogenic tissues since specific tropic hormones 
have not yet been identified. Cellular localization of 
growth factors in the placenta, including VEGF, EG-
VEGF and bFGF, points that these factors have 
additional roles in the organ besides their well known 
modulation on cell proliferation and angiogenesis. In 
vitro experiments bring new evidence that growth 
factors play regulatory roles modulating processes 
related to steroid hormone secretion in the placenta. 
Importance of local estrogen function has been 
highlighted and a key enzyme for its synthesis is 
aromatase cytochrome P450. The objective of this 
review was to describe some aspects of placental 
steroidogenesis, mainly focusing on aromatase 
cytochrome P450 steroidogenic enzyme expression and 
growth factors as others potential modulators of 
hormonal synthesis in the organ. 
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Introduction 
 
An important aspect in raising dairy and beef 
cattle is the optimization of reproductive performance 
and productive efficiency. Several studies have pointed 
out that cows, mainly those with high milk production, 
present a gradual increase in reproductive problems, 
apparently from multifactorial causes (Lucy, 2001), 
including negative energy balance (Goff and Horst, 
1997; Costa et al., 2007) and differential gene expression 
(Araújo et al., 2001). The placenta, beyond promoting 
maternal-fetal physiological exchange, synthesizes and 
secretes steroid hormones, such as progesterone and 
estrogens, which are responsible for the optimization of 
the environment for fetal growth (Hoffmann and 
Schuler, 2002). Therefore, its proper function is a 
determining factor for successful gestation. Regulatory 
mechanisms of placental function and activity, mainly 
those concerning the steroidogenic process, have not 
been totally explained yet. It is well described that 
estrogens are important regulators of caruncular growth 
and differentiation in the bovine placenta (Greven et al., 
2007) and that sulfotransferase gene family, involved in 
estrogen biodisponibility, are markedly expressed 
during placentogenesis (Ushizawa et al., 2007). Several 
studies have emphasized the role of VEGF, EG-VEGF 
and bFGF as essential regulators of vasculogenesis and 
angiogenesis during gestation. However, the 
localization of these growth factors and their respective 
receptors in non-endothelial cells points to their 
participation in other physiological functions, such as 
stimulation of hormonal production in steroidogenic 
tissues (Jablonka-Shariff et al., 1997; Yamamoto et al., 
1997; Winther et al., 1999; Winther and Dantzer, 2001). 
Thus, the aim of the present work was to review some 
aspects of placental steroidogenesis, mainly focusing on 
aromatase cytochrome P450 steroidogenic enzyme 
expression and growth factors as others potential 
modulators of hormonal synthesis in the organ. 
 
Placental steroidogenesis 
 
Steroid hormone synthesis starts when 
cholesterol, present in the cytoplasm, is transported to 
the inner mitochondrial membrane by steroidogenic 
acute regulatory protein - StAR (Herrmann et al., 2002; 
Sugawara and Fujimoto, 2004). Inside the mitochondrial 
inner membrane, the cholesterol side-chain cleavage 
cytochrome P450 enzymatic complex (P450scc) 
catalyzes the cholesterol conversion to pregnenolone 
(Hall, 1984). To form steroid hormones, the subsequent 
processing of pregnenolone requires enzymes related to 
smooth endoplasmic reticulum, such as 17α-hydroxylase/ 
C17, 20 – lyase (P450c17α) and 3β-hydroxysteroid-
dehydrogenase/isomerase (3β-HSD) (Carlone and 
Richards, 1997; Simpson and Davis, 2001), which 
belong to the Δ5 and Δ4 steroidogenic pathways (Fig. 1), 
respectively.  
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Figure 1. Principal steroidogenic pathways. Estrogen biosynthesis follows mainly the ∆5 pathway (gray chart). 
P450scc: cholesterol side-chain cleavage cytochrome P450; 3β-HSD: 3β-hydroxysteroid-dehydrogenase/isomerase; 
P450c17α: 17α-hydroxylase/C17, 20-lyase; P450arom: aromatase cytochrome P450. Adapted from Schuler et al., 1994. 
 
 
In Δ4 pathway, pregnenolone is converted to 
progesterone by the enzyme 3β-HSD, which in turn, is 
converted to androstenedione by the enzyme 17α-
hydroxylase/C17, 20 - lyase (P450c17α). On the other 
hand, in Δ5 pathway, the enzyme P450c17α converts 
pregnenolone to dehydroepiandrosterone (DHEA), while 
3β-HSD converts DHEA to androstenedione. 
Androstenedione is used as precursors for estrogen by 
trophoblastic cells (Albrecht and Pepe, 1990, 1998; 
Schuler et al., 1994). Estrogen biosynthesis is catalyzed 
by an enzymatic complex named aromatase cythocrome 
P450 (Conley and Hinshelwood, 2001). This complex 
binds the C19 steroid substrate (androstenedione and 
testosterone are the most common ones) and catalyzes 
specific reactions resulting in formation of phenolic A 
ring. NADPH cytochrome P450 reductase is an 
ubiquitous flavoprotein present in the endoplasmic 
reticulum of most cell types, which is responsible for 
transferring reducing equivalents to any microsomal 
form of cytochrome P450 (Simmons et al., 1985). 
P450arom is a member of a flourishing superfamily of 
genes, named the cytochrome P450 family, which
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contains at the present time more than 220 characterized 
members belonging to 36 gene families (Nelson et al., 
1993). In this context, P450arom is presently the sole 
member of gene family 19, designated Cyp19, based on 
the fact that the C19 angular methyl group is targeted by 
oxygen. The aromatase reaction apparently utilizes 3 mol 
oxygen and 3 mol NADPH for every metabolized C19 
steroid mol (Thompson and Siiteri, 1974). 
In cattle, estrone (E1) is the principal estrogen 
secreted throughout gestation, predominantly in its 
sulfoconjugated form - E1SO4 (Hoffmann et al., 1997; 
Zhang et al., 1999). Sites of estrogen production are the 
fetal cotyledons, which together with the maternal 
caruncular tissue, form multiple sites of placentation, 
the placentomes (Hoffmann et al., 1979; Robertson and 
King, 1979; Schuler et al., 1994). Placental estrogens 
can be detected in bovine fetal fluids as early as day 33 
of gestation, while in maternal plasma estrone sulfate 
concentrations start rising around day 70 (Eley et al., 
1979).  
Even though placental estrogen production 
starts in early gestation, focus on its biological role in 
cattle has been limited to preparation of genital tract for 
parturition and mammary glands for lactation. Detection 
of a high estrogen receptor α (ERα) expression in 
caruncular stromal and epithelial cells (Schuler et al., 
2002) shed new insights on the role of placental 
estrogens in cattle, classifying them primarily as local 
regulators of caruncular growth, differentiation and other 
functions throughout gestation (Greven et al., 2007). 
Moreover, the subsequent plasma estrone sulfate profile 
is used as an indicator of feto-placental developmental 
status and fetal viability (Zhang et al., 1999).  
Bovine placental steroidogenesis differs from 
that observed in other tissues, such as the ovaries, once 
it is not modulated by cyclic nucleotides as intracellular 
messengers (Ullmann and Reimers, 1989). It has been 
demonstrated that calcium (Ca++) acts as second 
messenger in steroidogenic stimuli signaling (Ullmann 
and Reimers, 1989) modulated by protein kinase C 
(Shalem et al., 1988; Shemesh et al., 1989) and 
calmodulin (Ullmann and Reimers, 1989). Moreover, 
the regulation of bovine placental steroidogenesis is still 
not elucidated, since specific tropic hormones have not 
yet been identified. In this case, the control of hormonal 
production is attributed to relative levels and tissue-
specific arrangement of steroidogenic enzymes (Izhar et 
al., 1992; Schuler et al., 2006).  
 
Control mechanisms of steroidogenic enzyme 
expression 
 
As previously mentioned, estrogen 
biosynthesis is catalyzed by aromatase cytochrome 
P450, which is encoded by the Cyp19 gene (Conley and 
Hinshelwood, 2001). In cattle, this gene has been 
mapped to band q2.6 of chromosome 10 (Goldammer et 
al., 1994). Although the length of the bovine Cyp19 
gene locus cannot be determined precisely, it may 
exceed 56 kb (Fürbass et al., 1997). The main sites of 
Cyp19 expression are the gonads (Masters et al., 2003; 
Mendelson et al., 2005) and, in humans and cattle, the 
placenta (Simpson et al., 1994; Corbin et al., 1995; 
Hinshelwood et al., 1995; Fürbass et al., 1997; Delarue 
et al., 1998; Vanseslow et al., 1999; Schuler et al., 
2006). However, during development, differentiation, 
and to a minor extent throughout adult life, Cyp19 
transcripts have been found in many organs, including 
skin, adipose tissue (Lueprasitsakul and Longcope, 
1991), brain (Harada et al., 1992; Lephard et al., 1992) 
and adrenal glands (Conley et al., 1996).   
In humans, tissue-specific expression of Cyp19 
is regulated by the use of various spatially separated 
promoter regions, resulting in transcripts variants with 
different 5’ untranslated regions (5’-UTRs), which are 
regulated by distinct hormones and second messengers 
(Clyne et al., 2004). On the contrary, sequences that 
encode P450arom protein remain identical (Mendelson et 
al., 2005). Thus, in humans, aromatase expression in the 
ovary is regulated by action of FSH through cAMP in the 
promoter II (Michael et al., 1995; Simpson et al., 2000), 
whereas in the placenta, promoter I.1 is stimulated in 
response to retinoids (Sun et al., 1998). Conversely, in 
adipose tissue, promoter I.4 drives Cyp19 expression under 
the control of glucocorticoids, class 1 cytokines or TNF-α 
(Zhao et al., 1995a,b, 1996). Although the alternative first 
exons are untranslated, their presence in the mature mRNA 
allows identification of the specific promoter used to 
derive a given transcript. 
Ruminants, horses and swine, which express 
P450arom in their placentas, also use placenta-specific 
promoter regions to regulate Cyp19 gene expression 
through alternative splicing (Hinshelwood et al., 1995). 
In the bovine placenta, two major Cyp19 transcript 
variants have been detected: one variant comprises exon 
1.1, and the other harbors exon 1.3 (Fürbass et al., 
1997). Upstream sequence to exon 1.1, namely 
promoter 1.1 (P1.1), has been identified as the promoter 
region responsible for Cyp19 gene expression in 
placenta (Hinshelwood et al., 1995; Fürbass et al., 1997; 
Vanseslow et al., 1999; Kalbe et al., 2000). The bovine 
P1.1 shows only 39% of sequence homology with the 
placenta-specific promoter of the human aromatase gene 
(Hinshelwood et al., 1995), but does not show any 
similarity with placenta-specific promoter 1.5 of ovine 
gene (Vanseslow et al., 1999). Furthermore, locations of 
these placenta-specific promoters are very different: 
whereas the bovine and human promoters are located far 
distal (Brunner et al., 1998; Kamat et al., 1999), the 
ovine promoter is located proximal to the translation 
start site (Vanseslow et al., 1999) as shown in Fig. 2. 
Thus, placenta-specific Cyp19 promoters are not 
homologous among species, suggesting that this gene 
was achieved independently several times during 
evolution, even in closely related species such as cattle 
and sheep (Fürbass et al., 2001). 
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Figure 2. Schematic representation of the human (a), bovine (b) and ovine (c) CYP19 gene. The coding region 
comprises exons II-X. Untranslated exons are shaded. The major placental promoter is the most distally located, and 
the ovarian promoter II is the most proximal. The main sites of expression are indicated under the first exons 
associated with CYP19 transcripts in each tissue. Since only exons II to X are translated, the protein products in each 
tissue are identical. 
 
 
The beginning of the transcription process is 
mediated by three types of RNA polymerases (I, II and 
III), specific for a genes’ single group transcription 
(Hib, 2003). Gene expression regulation is critically 
dependent on the chromatin structure (Felsenfeld et al., 
1996; Kadonaga, 1998), which is affected by DNA 
methylation patterns (Nan et al., 1998; Bhattacharya et 
al., 1999). DNA methylation is associated with more 
condensed chromatin and hence with transcriptional 
repression. However, during gene repression, the 
number of methylations has less influence than their 
location, since DNA methylation at promoter sequence 
can inhibit the activity of the gene, whereas several 
methylations at encoded regions do not modify them. In 
addition, one gene can be methylated in a cellular type, 
but not in another (Hib, 2003). 
P1.1 DNA is hypomethylated in the placental 
cotyledons and methylated in caruncles, testis and 
corpus luteum (Fürbass et al., 2001), suggesting that the 
fetal compartment shows high aromatase activity during 
gestation and parturition (Tsumagari et al., 1993). 
Furthermore, a survey of Cyp19 transcript variants 
presented a tissue specific distribution in cattle, in 
which abundant amounts of exon 1.1 transcripts were 
present in post-parturition placenta, containing the 
cotyledons, in contrast to low concentrations found in 
testis and corpus luteum (Fürbass et al., 1997).  
The bovine placental P1.1 region is an example 
of a promoter in which there is no consensus TATA 
motif, resulting in several transcription start sites within 
a stretch of 2023 bp. However, a putative transcriptional 
initiator region (INR) matching the consensus structure 
spans the major transcriptional start site 2 and is 
essential to position RNA polymerase II in the absence 
of consensus TATA motif (Fürbass et al., 1997). These 
elements are recognized by binding proteins that 
interact with cell general transcription machinery 
providing a proper environment for the formation of a 
competent transcriptional complex (Weis and Reinberg, 
1992). Thus, in this case the placental P1.1, consensus 
binding motifs for the ubiquitous upstream stimulating 
factor (USF) mediate the binding of a transcriptional 
factor IID with a deficient promoter TATA motif 
(Bungert et al., 1992). USF 1 and 2 act as 
transcriptional amplifiers (Gao et al., 2003; Nowak et 
al., 2005) and inhibitors of several target genes, 
including human placental Cyp19 gene (Jiang and 
Mendelson, 2005).  
In addition, although main human and bovine 
placenta-specific promoters (PI.1 and P1.1) are not 
related, both have binding sites to nuclear factor 
interleukin-6 (NF-IL6), which is a member of CEBP 
(CCAAT/enhancer binding protein) transcriptional 
factor family, characterized by containing a basic-
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leucine zipper domain required to form dimers and bind 
DNA (Akira et al., 1990). A hexameric sequence motif, 
AGGTCA (i.e. half of an estrogen receptor-binding site) 
occurs twice within P1.1. This motif has been reported 
as a steroidogenic factor – 1 (SF-1), also known as 
adrenal 4-binding protein – Ad4BP, binding site (Lala et 
al., 1992; Morohashi et al., 1992). 
SF-1 has emerged as a key regulator of 
endocrine function within the hypothalamic-pituitary-
gonadal axis and adrenal cortex and as an essential 
factor in sex differentiation. SF-1 was first identified as 
a transcription factor with limited tissue distribution that 
recognized a conserved regulatory motif in the proximal 
promoter regions of genes encoding the cytochrome 
P450 steroid hydroxylases. These studies established 
that SF-1 was responsible, at least in part, for tissue-
specific expression of genes involved in steroid 
hormone biosynthesis (Lynch et al., 1993; Morohashi et 
al., 1993; Parker and Schimmer, 1997). Subsequently, it 
has been demonstrated that SF-1 belongs to nuclear 
hormone receptor family (Honda et al., 1993), which 
represents a group of transcriptional factors mediating 
the actions of diverse ligands, including steroid 
hormones, thyroid hormone, vitamin D and retinoids 
(Mangelsdorf et al., 1995).  
Within SF-1 sequence, two transactivator 
domains have been identified: AF-2, responsible for 
binding of co-activators providing an essential function 
for the constitutive activity of SF-1 (Lund et al., 2002), 
and AF-1, which is regulated by mitogen-activated 
kinase (MAPK) phosphorylation and is involved in 
interactions with various cofactors and in stabilization 
of the AF-2 activating function (Crawford et al., 1997; 
Hammer et al., 1999; Desclozeaux et al., 2002).  
In the complex light of transcription regulating 
mechanisms, the multifaceted effects of hormones and 
growth factors on the development and function of 
tissues are described briefly. For example, ovarian 
follicular cells are under cyclic control by the 
differentiation-inducing gonadotropins FSH and LH, in 
combination with essential growth-promoting effects by 
hormones and growth factors like insulin and/or insulin-
like growth factor- I (McArdle et al., 1991). Synergistic 
activation by LH and IGF-1 appears to provide the full 
stimulus for ovarian follicular cell differentiation into 
luteal cells (Richards et al., 2002). Many of the genes 
induced or up-regulated during the luteinization process, 
for example genes coding for steroidogenic P450 
enzymes, steroid acute regulatory protein (StAR) and 
insulin-like factor-3 (INSL-3), appear to be controlled 
by SF-1 binding to specific binding sites in their 
promoter regions (Lala et al., 1992; Ivell et al., 1999). 
However, according to Walther et al. (2006), SF-1 
knockout indicates that it plays an important role in theca 
cells. Probably, the established activating functions of SF-1 
only play a minor role in the control of reproductive 
functions during theca cell luteinization, and an 
interconnection exists between MAP kinase and cyclic 
AMP-protein kinase-A pathways, constituting a non-
classical pathway of growth factor and hormone action. 
 
Growth factors 
 
Vascular endothelial growth factor (VEGF) and its 
receptors 
 
The VEGF family is constituted by various 
proteins identified by letters: VEGF-A to F (Paavonen 
et al., 1996; Achen et al., 1998; Meyer et al., 1999; Suto 
et al., 2005; Yamazaki et al., 2005), and placental 
growth factor - PLGF (Park et al., 1994). Native VEGF 
or VEGF-A is a heparin-binding homodimeric 
glycoprotein of 45 kDa, encoded by a single gene, and 
able to promote growth of vascular endothelial cells 
derived from arteries, veins and lymphatics (Ferrara, 
2004).  
Although endothelial cells are the primary 
targets of VEGF, several studies have reported 
mitogenic effects on certain nonendothelial cell types, 
including retinal pigment epithelial cells (Guerrin et al., 
1995), pancreatic duct cells (Oberg-Welsh et al., 1997), 
Schwann cells (Sondell et al., 1999), and possible 
regulatory actions on placental cell functions (Pfarrer et 
al., 2006a).  
Alternative exon splicing results in the 
generation of five different VEGF isoforms, which 
contain 120, 145, 165, 188 and 205 amino acids. The 
three smallest isoforms (VEGF120, VEGF145 and 
VEGF165) are diffusible and act in a paracrine manner, 
while the others (VEGF188 and VEGF205) are associated 
with the cellular membrane and act in an autocrine 
manner (Ferrara et al., 1992; Ng et al., 2006). VEGF 
primary transcript derives from a single gene organized 
in eight exons separated by seven introns. Alternative 
splicing involves exons 6 and 7, while the amino acids 
encoded by exons 1, 5, and 8 are conserved in all VEGF 
isoforms (Wellmann et al., 2001).  
Two tyrosine kinase receptors mediate VEGF 
biological activities: VEGFR-1/Flt-1 - Fms-like tyrosine 
kinase 1 (De Vries et al., 1992), and VEGFR-2/KDR - 
Kinase insert domain containing region (Terman et al., 
1992). Both VEGFR-1 and VEGFR-2 show seven Ig-
like structures in the extracellular domain, a single-
transmembrane region, and a tyrosine kinase sequence 
that is interrupted by a kinase-insert domain (Shibuya et 
al., 1990). VEGFR-3 or Flt-4 (Kaipainen et al., 1995) is 
another member of the same RTKs family, showing 
binding affinities for VEGF-C and VEGF-D 
(Karkhainen et al., 2002). In addition to RTKs, VEGF 
interacts with a family of coreceptors, the neurophilins 
(Ferrara, 2004). 
The interaction of VEGF with its receptors, Flt-1 
and KDR, occurs through two distinct domains present 
in VEGF molecule, which are located in the opposite 
terminal of VEGF monomer (Ferrara, 2004). VEGF165 
and VEGF188 activate Flt-1 (Plouet et al., 1997; Poltorak
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et al., 1997) while 120, 145, 165, and 188 isoforms 
activate KDR (Poltorak et al., 1997). In contrast, 
VEGF205 is a rare isoform, which is detected only in 
fetal liver and placenta (Burchardt et al., 1999), and is 
almost totally sequestered by extracellular matrix 
(Ferrara and Davis-Smith, 1997). 
In placentomes, VEGF system was located in 
uterine epithelium, trophoblast, as well as in vascular 
tissue and uterine glands. The presence of VEGF system 
in the maternal-fetal interface, and in vasculature 
indicates that bovine VEGF may have: (1) classical 
functions in angiogenesis and vascular permeability, (2) 
chemotactic activity in endothelial capillaries, (3) 
autocrine influence in giant trophoblastic cells 
migration, which facilitates maternal-fetal interchange 
(Pfarrer et al., 2006a), and (4) modulatory action in 
trophoblastic function (Winther and Dantzer, 2001), 
specifically in steroidogenesis. 
 
Endocrine gland-derived vascular endothelial growth 
factor (EG-VEGF) and its receptors 
 
Endocrine gland derived endothelial growth 
factor is a recently identified angiogenic factor, which 
expression of mRNA and protein is restricted to 
endocrine glands (Le Couter et al., 2001). Other organs, 
like the small intestine, may contain lower levels of this 
factor (Li et al., 2001). Also known as prokinectin 1 
(PK-1), EG-VEGF binds to two closely homologous G-
protein coupled receptors (PK-R1 and PK-R2), inducing 
the enhancement of cell proliferation and survival 
(Kisliouk et al., 2005). It has been demonstrated that 
EG-VEGF allows the development of endothelial 
fenestrations, increasing vascular permeability (Le 
Coulter et al., 2001). This effect promotes the transport 
of LDLs (low density lipoproteins) into the 
steroidogenic cells, which secrete progesterone and 
other products into the bloodstream (Fraser et al., 2005) 
and highlights its role as a pro-survival factor.   
Moreover, EG-VEGF is able to increase the 
VEGF mRNA expression affecting angiogenesis 
directly and indirectly (Kisliouk et al., 2005). In the first 
trimester human placenta, it has been demonstrated that 
EG-VEGF mRNA peaks in the ninth gestational week, 
whereas VEGF mRNA peaks in the seventh and remains 
elevated (Hoffmann et al., 2006). Levels of EG-VEGF 
receptors mRNA are not correlated to each other during 
human pregnancy: PK-R1 mRNA shows the same 
expression profile as EG-VEGF, while PK-R2 increases 
in the end of the first gestational trimester (Hoffmann et 
al., 2006). Protein expression of EG-VEGF reflects 
mRNA findings: immunohistochemistry tests localized 
EG-VEGF mainly in the syncytiotrophoblast layer at the 
sixth and also in the cytotrophoblast at the eigth and 
ninth gestational weeks (Hoffmann et al., 2006). 
Cellular localization of VEGF was adjacent but distinct 
from that for EG-VEGF, suggesting both factors may 
play complementary biological roles in the human and 
mouse placenta (Hoffmann et al., 2006, 2007) and also 
corpus luteum (Chung et al., 2004).  
A functional hypoxia-response element 
(TACGTGCGGC) was localized to the promoter region 
of human EG-VEGF gene (Le Couter et al., 2001). In 
fact, EG-VEGF transcription and translation are 
regulated by hypoxic conditions. Other potential 
regulators of the EG-VEGF gene are luteinizing 
hormone, human chorionic gonadotropin (Fraser et al., 
2005) and progesterone, specifically for the 
endometrium (Battersby et al., 2004; Fraser et al., 
2005). However, other factors, presenting expression 
peaks in the first gestational trimester may also act as 
regulators of EG-VEGF gene and protein expression 
(Hoffmann et al., 2006). 
PK-R1 (EG-VEGFR1) and PK-R2 (EG-
VEGFR2) are G-Protein coupled receptors showing 
85% amino acid sequence homology. In the human 
placenta both receptors are found; trophoblast cells 
express large amounts of PK-R1 between the eight and 
tenth weeks of gestation, exactly during the time in 
which the placenta undergoes developmental hypoxia. 
Like EG-VEGF, but not PK-R2, PK-R1 seems to be 
modulated by hypoxia (Hoffmann et al., 2006). The 
exact localization of PK-R1 and PK-R2 could be 
elucidated using mouse placenta and house produced 
antibodies against these proteins. Labyrinth was the 
major expression site for both PK-R1 and PK-R2 during 
the whole gestation, although PK-R1 could not be 
detected after day 14 post-coitus (Hoffmann et al., 
2006, 2007). Both receptors have already been isolated 
from different body compartments like gut, nervous 
system and endocrine glands, pointing towards 
functional flexibility. PK-R1 and PK-R2 are activated 
by nanomolecular concentrations of recombinant EG-
VEGF, leading to calcium, IP3 and MAPK mobilization 
(Lin et al., 2002a,b; Masuda et al., 2002). 
 
Fibroblast growth factors (FGFs) and their receptors 
 
Fibroblast growth factors (FGFs) are small 
polypeptide growth factors, sharing common structural 
features. To date, twenty-five distinct FGFs have been 
identified, numbered consecutively from 1 to 25 (Katoh 
and Katoh, 2005). FGFs induce mitogenic, chemotactic, 
and angiogenic activity in cells of mesodermal and 
neuroectodermal origin (Basilico and Moscatelli, 1992). 
FGF family has a strong affinity for heparin and 
HLGAGs (Burgess and Maciag, 1989), as well as a 
central core of 140 amino acids that is highly conserved 
among different family members.  Despite 
nomenclature, the use of FGF initials does not mean that 
all factors stimulate fibroblast activities (indeed, FGF-7 
does not stimulate fibroblasts) but rather that they 
belong to the same family due their structural 
similarities (Zhu et al., 1991). 
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Alternative exon splicing of bFGF (FGF-2) 
gene results in the generation of five distinct isoforms 
with 18, 22, 22.5, 24 and 34-kDa (Arnaud et al., 1999; 
Okada-Ban et al., 2000). This alternative splicing 
regulates the localization of the isoforms in cells, and 
can modulate their function (Bugler et al., 1991). The 
18-kDa form is located in the cytoplasm (Renko et al., 
1990; Bugler et al., 1991; Yu et al., 1993; Davis et al., 
1997) acting in a paracrine/autocrine manner (Bikfalvi 
et al., 1995; Davis et al., 1997; Arese et al., 1999). In 
contrast, the high molecular weight forms are located in 
the nucleus (Renko et al., 1990; Bugler et al., 1991; Yu 
et al., 1993; Davis et al., 1997) and exert their effects in 
an intacrine manner, independent of receptor activation 
(Bikfalvi et al., 1995; Davis et al., 1997; Arese et al., 
1999). 
FGFs produce their mitogenic and angiogenic 
effects in target cells by signaling through cell-surface, 
tyrosine kinase receptors. Five distinct genes encode the 
high affinity receptors: FGFR-1 to 5 (Sleeman et al., 
2001). All FGFRs have one extracellular domain, a 
single-transmembrane region, and a tyrosine kinase 
domain. The extracellular portion comprises three Ig-
like domains, D1, D2, and D3 (Stauber et al., 1999). 
Alternative splicing in exon III results in the 
generation of three isoforms of FGFR-1, FGFR-2 and 
FGFR-3 (IIIa, IIIb and IIIc), which present different 
degrees of affinity with FGFs. For example, FGF-1 
activates all variants, while bFGF activates mainly IIIc 
isoforms (Coleman, 2003). Isoform IIIa is a truncated 
protein unable to translate extracellular signaling 
(Ornitz et al. 1996; Igarashi et al. 1998). The fifth FGF 
receptor differs from the others because it has one 
membrane protein, and an extracellular domain 
composed of 16 cysteines (Stauber et al., 1999). 
Both maternal and fetal tissues express bFGF 
throughout gestation (Rider and Piva, 1998; Zheng et 
al., 1998), indicating that it is an essential factor for 
differentiation of vascular and nonvascular mesoderm-
derived tissues (Yamaguchi and Harpal, 1994; Reynolds 
et al., 2000). In bovine placenta, bFGF was localized in 
epithelial cell cytoplasm, maternal and fetal stroma, as 
well as in endothelial cells. Both FGFR-1 and FGFR-2 
were observed in cytoplasm and nucleus of epithelial 
cells, maternal and fetal stroma, and endothelial cells, 
while FGFR-3 presented predominantly nuclear 
localization in all cell types throughout gestation. 
According to Pfarrer et al. (2006b), in cattle, members 
of FGF family are located specifically in giant 
trophoblast cells, suggesting that these cells exert 
classical hormonal production function, beyond playing 
important roles in the regulation of placental growth, 
differentiation, and angiogenesis. 
An intimate cross-talk exists among bFGF and 
the different members of the VEGF family during 
angiogenesis, vasculogenesis, and lymphangiogenesis. 
Experimental evidence points to the possibility that 
bFGF induces neovascularization indirectly by 
activation of the VEGF/ VEGFR system (Sheghezzi et 
al., 1998; Auguste et al., 2001; Tille et al., 2001; Gabler 
et al., 2004). Concerning hormone production 
modulation, a cross-talk mechanism among bFGF and 
VEGF could not be excluded. 
 
Steroidogenesis modulated by growth factors 
 
Functional studies related to role of growth 
factors on steroidogenesis modulation are described for 
VEGF and bFGF, but not EG-VEGF. In vitro studies 
demonstrate that VEGF and bFGF exert modulatory 
effects in cell steroidogenesis from distinct species. 
Both VEGF and bFGF influence estradiol-17β and 
progesterone production in swine granulosa cells 
(Grasselli et al., 2002), and increase progesterone 
production in early bovine corpus luteum (Kobayashi et 
al., 2001). Modulation of FSH-induced steroidogenesis 
by bFGF, inhibits estradiol-17β and progesterone 
synthesis in bovine (Vernon and Spicer, 1994) and 
mouse granulosa cells (Yamoto et al., 1993), as well as 
androstenedione production in chicken granulosa cells 
(Li and Johnson, 1993). Furthermore, both VEGF and 
bFGF act in bovine placenta in a paracrine and/or 
autocrine manner, increasing progesterone synthesis 
depending on gestational stage. 
Until now, evidence about the possible 
influence of VEGF, EG-VEGF and bFGF in placental 
estrogen synthesis does not exist. Although 
experimental data demonstrate effects of these growth 
factors in ovarian and corpus luteum steroidogenesis, 
they do not explain totally if their action is mediated 
though direct effect on steroidogenic enzymes or not. 
For example, inhibition of cytochrome P450 17α-
hydroxylase expression mediates the inhibitory effect of 
bFGF on androstenedione production from chicken 
granulosa cells (Li and Johnson, 1993), but VEGF and 
bFGF progesterone stimulation in early bovine corpus 
luteum is possibly mediated by the influence of these 
factors on the luteal secretion of prostaglandin F2α and 
angiotensin II (Kobayashi et al., 2001). 
The regulation of bovine placental 
steroidogenesis can be characterized as a multifactorial 
process, where locally produced hormones, cytokines 
and growth factors, including VEGF and bFGF, 
participate in an autocrine and/or paracrine manner, to 
play decisive roles in fetal development and successful 
reproduction.  
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